GenoMEL logo
 
 
  GenoMEL is an international research consortium coordinated by the University of Leeds.
  University of Leeds
  home
  Nieuws
  Programma
  Lidmaatschap
  Deelnemers
  Medische informatie
  Patiënteninformatie
  Artikelen
  Exchange Programme
  data sharing
  Knowledge Transfer
  Leden sectie
  Stage III Melanoma Research Group
  PharmacoGenoMEL
  Contact
  Site Map
  media
  Doorzoeken van de site
  Interessante links
  Kies een andere taal
  Toegang
  Terms and Conditions
Privacy Statement
  Translations by: The LUMC team, particularly Frans van Nieuwpoort
Participants
EVRY, France
 
Group Details Group Members Group Publications
 
Group Details
   

Title and address of our institution

INSERM – UNIVERSITE D’EVRY
Tour Evry 2 - Génopole“
523 Place des Terrasses de l’Agora
91034 Evry
FRANCE

INSTITUT GUSTAVE ROUSSY
39 rue Camille Desmoulins
94805 Villejuif
FRANCE

 
 

Title and address of our group

EMI-0006 – INSERM–UNIVERSITE D’EVRY (Genetic Epidemiology)
Tour Evry 2
523 Place des Terrasses de l’Agora
91034 Evry
France

Department of Dermatology (dermatology clinic)
Department of Genetics
(molecular genetics)
Department of Medicine
(oncogenetics)
Institut Gustave Roussy
39 rue Camille Desmoulins
94805 Villejuif
France

 
 

The name, address and contact e-mail, tel of the group leader

Dr. Florence Demenais, MD
EMI-0006 – INSERM - UNIVERSITE D’EVRY
Tour Evry 2 - 523 Place des Terrasses de l’Agora
91034 Evry
France

E-mail: demenais@evry.inserm.fr
Phone: 33-1-60-87-3826
Fax: 33-1-60-87-3848

 
 

A paragraph describing the group

Our melanoma research program is a multidisciplinary program involving clinicians, molecular biologists and onco-geneticists from Institut Gustave Roussy and genetic epidemiologists from INSERM-Université d’Evry, working with a network of Dermatologists and Oncogeneticists.

The overall objective of our research program is to identify inherited genes and gene-environment interactions involved in melanoma pathogenesis. Large collections of data have been established over the past 15 years including families ascertained through one melanoma proband, families with at least two melanoma cases and more recently sporadic cases with multiple primary melanomas and/or young age at onset suggesting genetic predisposition. The main outcomes of this program are summarized as follows.

The rate of CKDN2A mutations identified in melanoma-prone families is one of the highest rates reported worldwide in clinically-selected families. One of these mutations (G101W) demonstrated a founder effect common to French, Italian, Spanish and North-American pedigrees and was also found in sporadic cases indicating a highly variable expression of this mutation. More recently, a CDKN2A mutation (Gly67Ser) was found to co-segregate with both cutaneous and uveal melanoma in one pedigree showing that CDKN2A is also an uveal melanoma predisposing gene. In the search for new melanoma predisposing genes, the BRAF gene, for which a high frequency of somatic mutations was reported in melanoma cell lines, primary tumors and nevi, did not appear to predispose to melanoma in our population.

Segregation analysis, based on methodology developed by our group, showed significant evidence for a major gene segregating in families ascertained systematically through one melanoma proband; interestingly the penetrance of this gene (reaching 49% in males and 67% in females by age 80 years) was similar to that of CDKN2A gene estimated in the European families of the International Melanoma Consortium. Moreover, the same factors increased the penetrance of this gene and that of CDKN2A in our French family samples: nevus phenotypes (high number of nevi, dysplastic nevi) and sunburns with a marginal effect of high degree of sun exposure. More recently, variants of MC1R gene, known to be involved in human pigmentation, were found to increase CDKN2A penetrance in addition to dysplastic nevi and sunburns in French melanoma-prone pedigrees. In addition, significant evidence for familial aggregation of melanoma risk factors was found in our series of families with at least two melanoma cases, these patterns of familial clustering being compatible with the influence of genetic factors for phototype and high number of nevi and shared environment for sun exposure.

The future aims of our research program include the search for high-risk genes in CDKN2A negative melanoma-prone families, the identification of genetic variants in candidate genes accounting for cases with low familial clustering and multiple sporadic melanoma and the characterization of gene-gene as well gene-environment interactions. A genetic study of the high number of nevi has also been undertaken that will include a genome-wide scan to characterize the chromosomal regions of interest to be further explored towards gene identification.

Our group is also involved in other research projects including clinical research on melanoma (Institut Gustave Roussy), molecular genetic studies of other cancers (Institut Gustave Roussy), as well as development of methodology in statistical genetics and genetic epidemiology of other multifactorial diseases (EMI-0006).

 
 

Related Links

Institut Gustave Roussy (IGR)
www.igr.fr

Institut National de la Santé et de la Recherche Médicale (INSERM)
www.inserm.fr

Université d’Evry
www.univ-evry.fr

Génopole
www.genopole.org

 
 
 
   
 
 
   
website design: NKD | email: info@NKD.org.uk | site: www.NKD.org.uk